USFDA issues 14 observations to Aurobindo Pharma's Pashamylaram facility; shares slump 9%
Updated : November 14, 2019 12:22 PM IST
US FDA issues a 'Form 483' with 14 observations to its Unit IV of Aurobindo Pharma
Unit IV is a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more